Leverages Advanced Magnetic Bead-Based Technology to Support Next Gen Sequencing, Genotyping, PCR and MLPA in Human Samples
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the launch of its chemagic™ Prime™ instrument, a new streamlined, walk-away sample processing solution which offers automated nucleic acid isolation and assay setup by combining PerkinElmer’s chemagic™ 360 instrument with the JANUS® automated liquid handling system.
Researchers specializing in biobanking, genetics and next generation sequencing can leverage the chemagic Prime technology to streamline and automate high quality DNA and RNA extraction for a wide range of human samples. Obtained nucleic acids can be used for a huge variety of downstream assays including (but not limited to) next generation sequencing, genotyping, PCR and MLPA.
American Society of Human Genetics (ASHG) Annual Meeting
Orange County Convention Center, South Building
PerkinElmer Booth #617
HOW IT WORKS:
The chemagic Prime instrument uses magnetized rods rather than magnetic plates to separate nucleic acids from solutions. Transferring the magnetic beads instead of the process solutions reduces contamination risk and isolates higher purity, more intact DNA and RNA. By incorporating additional liquid handling capabilities, the chemagic Prime instrument also automates primary sample transfer, normalization, and setup of PCR assays and NGS libraries, making the chemagic Prime instrument a complete, automated solution for walk-away sample processing.
The chemagic Prime instrument can pair with PerkinElmer’s reagent kits for isolating nucleic acids from a variety of human samples including whole blood, saliva, plasma, tissues, FFPE samples, and feces.
The chemagic Prime instrument offers flexibility in sample input volumes and a short processing time, while eliminating cross contamination. It delivers high yields of high quality nucleic acids, including high molecular weight DNA.
The chemagic Prime technology also provides post-extraction capabilities including automated sample tracking and primary sample handling, which reduces the amount of manual handling required for nucleic acid isolation.
“As the critical prerequisite for many downstream applications in next generation sequencing and PCR analysis, nucleic acid isolation forms the foundation for groundbreaking research,” said Masoud Toloue, Ph.D., Vice President and General Manager of Applied Genomics, PerkinElmer. “The market is moving toward magnetic bead-based systems because of their continuity, safety and full traceability, and our new chemagic Prime solution offers them a proven, single-supplier workflow.”
PerkinElmer’s diagnostics solutions enable advances in reproductive health, infectious disease screening and genomics through its broad range of instruments, reagents, assay platforms and software offerings.
PerkinElmer, Inc. is a global leader committed to innovating for a healthier world. Our dedicated team of 9,000 employees worldwide is passionate about providing customers with an unmatched experience as they help solve critical issues especially impacting the diagnostics, discovery and analytical solutions markets. Our innovative detection, imaging, informatics and service capabilities, combined with deep market knowledge and expertise, help customers gain earlier and more accurate insights to improve lives and the world around us. The Company reported revenue of approximately $2.1 billion in 2016, serves customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com